西安交通大学学报（医学版）2026，Vol.47Issue(1)：25-31,7.DOI:10.7652/jdyxb202601004
阿尔茨海默病Aβ免疫治疗规范与流程
Standardization and process of Aβ immunotherapy for Alzheimer's disease
摘要
Abstract
In 2024 anti-β-amyloid(Aβ)monoclonal antibodies(Lecanemab and Donanemab)were approved to enter the market at home and abroad.They are gradually used in clinical practice.In order to promote the more reasonable and safer application of anti-Aβ monoclonal antibodies in the treatment of Alzheimer's disease(AD)in China,this article summarizes the existing clinical trial evidence of anti-Aβ monoclonal antibodies and some experience in the clinical application.The clinical treatment specifications and processes of monoclonal antibodies,including clinical drug indications,pre-medication evaluation and preparation,medical instructions and precautions during medication,and post-medication clinical monitoring,are constructed to build a standardized treatment system for AD,and the plateau adaptability plan is optimized,aiming to provide clinicians with detailed medication guidance and suggestions,and further promote the standardization and precision of AD treatment.关键词
阿尔茨海默病(AD)/β-淀粉样蛋白(Aβ)/免疫治疗/治疗规范/管理流程Key words
Alzheimer's disease(AD)/β-amyloid(Aβ)/immunotherapy/standardized treatment/management process分类
医药卫生引用本文复制引用
高森森,李娜,钟欣,张桂娟,朱爱琴..阿尔茨海默病Aβ免疫治疗规范与流程[J].西安交通大学学报（医学版）,2026,47(1):25-31,7.基金项目
科技部科技创新2030"脑科学与类脑研究"重大项目(No.2022ZD0211602) （No.2022ZD0211602）
青海省科技厅应用基础研究项目(No.2021-ZJ-756)Supported by the Ministry of Science and Technology Science and Technology Innovation 2030"Brain Science and Brain-like Research"Major Project(No.2022ZD0211602)and Qinghai Provincial Department of Science and Technology Applied Basic Research(No.2021-ZJ-756) （No.2021-ZJ-756）
